z-logo
Premium
Protective effect of Gallic acid on doxorubicin‐induced testicular and epididymal toxicity
Author(s) -
Olusoji M.J.,
Oyeyemi O. M.,
Asenuga E. R.,
Omobowale T. O.,
Ajayi O. L.,
Oyagbemi A. A.
Publication year - 2017
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.12635
Subject(s) - malondialdehyde , toxicity , oxidative stress , glutathione , sperm , endocrinology , testosterone (patch) , medicine , reproductive toxicity , pharmacology , antioxidant , chemistry , epididymis , gallic acid , doxorubicin , andrology , chemotherapy , enzyme , biochemistry
Summary The effect of Gallic acid ( GA ) on doxorubicin ( DOX )‐induced testicular and epididymal toxicity was investigated in experimental rat model. The rats were randomly divided into six groups of 10 animals per group. Rats in group A received clean tap water ad libitum. Rats in group B were administered DOX intraperitoneally at 15 mg/kg on the eighth day of the experiment. Animals in groups C and D received 60 and 120 mg/kg GA orally for 7 days with 15 mg/kg DOX on the eighth day. Rats in groups E and F received 60 and 120 mg/kg GA alone orally for 7 days. The animals were sacrificed 24 hr after the last administration. DOX administration led to a significant ( p  < 0.05) increase in hydrogen peroxide and malondialdehyde levels with significant reduction in antioxidant enzymes and reduced glutathione levels. DOX administration also led to a significant increase in total sperm abnormalities and prolactin together with a significant decrease in testosterone levels. Immunohistochemistry revealed higher expressions of caspase 3 in the testicular tissues of rats that received DOX alone. Together, pre‐treatment with GA attenuated markers of oxidative stress, reversed sperm abnormality and ameliorated the observed aberration in plasma testosterone and prolactin levels.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here